Back
AbbVie 10K Form
Sell
31
ABBV
AbbVie
Last Price:
167.73
Seasonality Move:
6.01%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2024-05-03 | 10Q | ABBV/AbbVie Quarterly |
| 2023-11-06 | 10Q | ABBV/AbbVie Quarterly |
| 2023-08-07 | 10Q | ABBV/AbbVie Quarterly |
| 2023-05-05 | 10Q | ABBV/AbbVie Quarterly |
| 2022-11-04 | 10Q | ABBV/AbbVie Quarterly |
| 2022-08-04 | 10Q | ABBV/AbbVie Quarterly |
Receive ABBV News And Ratings
See the #1 stock for the next 7 days that we like better than ABBV
ABBV Financial Statistics
Sales & Book Value
| Annual Sales: | $54.32B |
|---|---|
| Cash Flow: | $5.2B |
| Price / Cash Flow: | 19.04 |
| Annual Sales: | $3.41 |
| Price / Book: | 49.15 |
Profitability
| EPS (TTM): | 2.88000 |
|---|---|
| Net Income (TTM): | $5.12B |
| Gross Margin: | $33.9B |
| Return on Equity: | 58.92% |
| Return on Assets: | 3.63% |
AbbVie Earnings Forecast
Key AbbVie Financial Ratios
- The Gross Profit Margin over the past 15 years for ABBV is 62.42%.
- The Selling, General & Administrative Expenses for ABBV have been equal to 23.70% of Gross Profit Margin.
- The Research & Development expenses have been 15.56% of Revenue.
- The Interest Expense is 45.73% of Operating Income.
- The Net Earning history of ABBV is 8.95% of Total Revenues.
- Per Share Earnings over the last 15 years have been positive in 7 years.
AbbVie Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | S&P500 |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | ABBV |
| CUSIP: | 00287Y |
| Website: | abbvieinvestor.com |
Debt
| Debt-to-Equity Ratio: | 11.78 |
|---|---|
| Current Ratio: | 0.65 |
| Quick Ratio: | 0.44 |
Price-to-Earnings
| Trailing P/E Ratio: | 61.68 |
|---|---|
| Forward P/E Ratio: | 13.81 |